drugset / Trial / NCT01465243

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

NCT01465243

Phase 4 Completed 32 enrolled Betta Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.

Timeline

Start
2011-09
Primary completion
2013-10
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule 125 mg
Subject Icotinib Small molecule 250 mg